Genzyme Corp., which is fighting off a hostile $18.5 billion bid from Sanofi-Aventis SA, is taking another stab at persuading investors that its experimental multiple sclerosis drug is worth more than Sanofi’s projections.
*For more on this story, read the full Reuters article.
